MARIO GUIMARAES PESSOA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
14 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 14
conferenceObject EFFECTIVENESS OF THE IMPLEMENTATION OF A RE-LINKAGE TO CARE STRATEGY IN PATIENTS WITH HEPATITIS C WHO WERE LOST OF FOLLOW-UP(2021) MENDIZABAL, Manuel; THOMPSON, Marcos Andres; RIDRUEJO, Ezequiel; BALLERGA, Esteban Gonzalez; VELASCO, Jose Antonio Velarde Ruiz; PALAZZO, Ana; MEZZANO, Gabriel; ESPINOSA, Linda Elsa Munoz; PESSOA, Mario; REYES, Eira Cerda; SOZA, Alejandro; RUIZ, Sandro; GOMEZ-ALDANA, Andres Jose; GERONA, Solange; FUSTER, Francisco; ANDERS, Margarita; VALDIVIA, Flor De Maria Beltran; PONIACHIK, Jaime; SCHINONI, Maria Isabel; HERNANDEZ, Nelia; MONTES, Pedro; GIRALA, Marcos; CASTILLO, Lida; CASTILLO-BARRADAS, Mauricio; CHAVEZ, Rocio; CABRERA, Cecilia; TENORIO, Laura; ZEVALLOS, Katherine; GARAVITO, Jorge; BRUTTI, Julia; TAGLE, Martin; NARRO, Graciela Castro; POZO, Emilia Vera; PERAZZO, Rosalia; TORO, Luis Guillermo; VARON, Adriana; FERREIRO, Melina; LAZCANO, Monserrat; MURGA, Maria Dolores; GOMEZ, Fernando; HERNANDEZ, Larissa; MOUTINHO, Bruna Damasio; GANDARA-CALDERON, Julian; VARGAS, Jose Ignacio; SIMIAN, Daniela; SILVA, MarceloconferenceObject YSTRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS(2023) DIAZ, Luis Antonio; GARCIA, Sergio; AYARES, Gustavo; URIBE, Javier; IDALSOAGA, Francisco; FUENTEALBA, Jose Miguel; FUENTES-LOPEZ, Eduardo; MEDEL, Maria Paz; RAMIREZ-CADIZ, Carolina A.; KHAN, Rayan; LAZO, Mariana; FERRECCIO, Catterina; MENDIZABAL, Manuel; DIRCHWOLF, Melisa Melisa; SALAZAR, Patricia Guerra; OLIVEIRA, Claudia P. M. S.; PESSOA, Mario G.; ALVARES-DA-SILVA, Mario R.; SEBASTIANI, Giada; BRAHMANIA, Mayur; RAMJI, Alnoor; NIAZI, Mina; KO, Hin Hin; FELD, Jordan J.; RESTREPO, Juan Carlos; QUESADA, Wagner Enrique Ramirez; ALFARO, Omar; FERNANDEZ, Marlen Ivon Castellanos; ESTUPINAN, Enrique Carrera; AGUIRRE, Jose Roberto; MALDONADO, Katherine; SANCHEZ, Abel; SANCHEZ, Marco; SR., Teresa Andara; CASTRO-NARRO, Graciela Elia; CHAVEZ-TAPIA, Norberto Carlos; MENDEZ-SANCHEZ, Nahum; ADAMES-ALMENGOR, Enrique; LOMBARDO, Julissa; SR., Marcos Girala; MORAN, Elias; PADILLA-MACHACA, Martin; FERRER, Javier Diaz; TAGLE, Martin; MAINARDI, Vitoria; HERNANDEZ, Nelia; MARTINEZ, Edmundo; ALVARADO-TAPIAS, Edilmar; LEON, Roberto; TALAL, Andrew; THOMAS, Emmanuel; SPRINGER, Sandra; SICILIA, Mauricio Garcia Saenz de; ZHANG, Wei; BAJAJ, Jasmohan S.; TAPPER, Elliot B.; IZZY, Manhal; GISH, Robert G.; ATTAR, Bashar M.; COTTER, Thomas G.; LUCEY, Michael R.; KAMATH, Patrick S.; SINGAL, Ashwani K.; BATALLER, Ramon; MEZZANO, Gabriel; SOZA, Alejandro; LAZARUS, Jeffrey V.; ARRESE, Marco; ARAB, Juan PabloconferenceObject 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS(2012) PIRATVISUTH, T.; KOMOLMIT, P.; TANWANDEE, T.; SUKEEPAISARNJAROEN, W.; CHAN, H. L.; PESSOA, M. G.; FASSIO, E.; ONO-NITA, S.; BESSONE, F.; DARUICH, J.; ZEUZEM, S.; CHEINQUER, H.; DONG, Y.; TRYLESINSKI, A.Background and Aims: The roadmap concept based on Week 24 HBV DNA levels was prospectively validated with 1year results of Roadmap study (A2410) as previously reported. The 2 year results are reported here. Patients and Methods: All patients were HBeAg positive and started LDT monotherapy from baseline and Tenofovir (LDT) was added to patients with detectable (≥300 copies/ml) HBV DNA at 24w until 104w. Results: 105 patients were enrolled and 100 patients were eligible for modified ITT (mITT) analysis (1 patient with baseline M204I mutation, 2 lost follow-up and 2 didn’t follow roadmap concept). At 24w, 55 patients achieved undetectable HBV DNA and 45 patients with detectable HBV DNA added with TDF (73% of the 45 patients with baseline HBV DNA > 9log10 copies/ml). At 104w, 94% had undetectable HBV DNA, 50%/44% HBeAg loss/seroconversion, 7%/4% HBsAg loss/seroconversion. One patient in LDT mono-treated arm had Virologic Breakthrough (VB) at Week 72 and detected M204I mutation; achieved undetectable HBV DNA 8wks after TDF add-on. One LDT mono-treated patient had one time of HBV DNA increase of 1 log10 above nadir (assessment ongoing). Both patients had baseline HBV DNA > 9log10 copies/ml. In the overall safety population, Serious Adverse Events (SAEs) was reported in 6/105 (5.7%) patients and all unrelated to treatment. No case of myopathy/myositis was reported. Overall GFR (by MDRD formula) improvement was +6.4 and +8.6ml/min/1.73m2 in LDT mono and LDT+TDF group respectively. In patients with abnormal baseline GFR (60–90ml/min/1.73m2), GFR improvement at 2yr was +12.0 and +1.5ml/min/1.73m2 in LDT and LDT+TDF respectively. 50% and 40% of patients with abnormal baseline GFR (60–90ml/min/1.73m2) in LDT and LDT+TDF group respectively shifted to normal (>90ml/min/1.73m2) at 2yr. Only 1 patient in TDF add-on group had once creatinine increase to 232 μmol/L at Week 96, and returned to 91 μmol/L within 4 days. Conclusion: Telbivudine roadmap with tenofovir add-on at 24 weeks in patients with detectable HBVDNA improved GFR in both LDT and LDT+TDF treated patients, as well as favorable efficacy and safety profiles.- Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment(2020) PINERO, Federico; DIRCHWOLF, Melisa; PESSOA, Mario G.Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and treatment strategies to improve the prognosis of this malignancy. The identification of useful biomarkers for surveillance and early HCC diagnosis is still deficient, with available serum biomarkers showing low sensitivity and heterogeneous specificity despite different cut-off points, even when assessed longitudinally, or with a combination of serum biomarkers. In contrast, HCC biomarkers used for prognostic (when associated with clinical outcomes) or predictive purposes (when associated with treatment response) may have an increased clinical role in the near future. Furthermore, some serum biomarkers are already implicated as a treatment selection tool, whether to provide access to certain therapies or to assess clinical benefit after treatment. In the present review we will discuss the clinical utility and foreseen future of HCC biomarkers implicated in surveillance, diagnosis, prognosis, and post-treatment assessment.
- Preface: A CLD Collaboration With the Latin American Association for the Study of the Liver (ALEH)(2019) PESSOA, M.G.; MENDIZABAL, M.
- The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease(2021) MENDEZ-SANCHEZ, Nahum; ARRESE, Marco; GADANO, Adrian; OLIVEIRA, Claudia P.; FASSIO, Eduardo; ARAB, Juan Pablo; CHAVEZ-TAPIA, Norberto C.; DIRCHWOLF, Melisa; TORRE, Aldo; RIDRUEJO, Ezequiel; PINCHEMEL-COTRIM, Helma; FERNANDEZ, Marlen Ivon Castellanos; URIBE, Misael; GIRALA, Marcos; DIAZ-FERRER, Javier; RESTREPO, Juan C.; PADILLA-MACHACA, Martin; DAGHER, Lucy; GATICA, Manuel; OLAECHEA, Blanca; PESSOA, Mario G.; SILVA, MarceloThe Latin American Association for the Study of the Liver (Asociacion latinoamericana para el Estudio del Higado; ALEH) represents liver professionals in Latin America with the mission of promoting liver health and quality patient care by advancing the science and practice of hepatology and contributing to the development of a regional health policy framework. Fatty liver disease associated with metabolic dysfunction is of specific concern in the ALEH region, where its prevalence is one of the highest globally, second only to the Middle East. A recent consensus from an international panel recommended a new definition of fatty liver disease associated with metabolic dysfunction, including a shift in name from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), and adoption of a set of positive criteria to diagnose the disease, independent of alcohol intake or other liver diseases. Given, the importance of this proposal, ALEH invited leading members of regional nations to come to a consensus on it from a local perspective. We reached a consensus to endorse the proposal that the disease should be renamed as MAFLD and that the disease should be diagnosed by the proposed simple and easily applicable criteria. We expect that this change in nosology will result in improvements in disease awareness and in advances in scientific, economic, public health, political, and regulatory aspects of the disease.
conferenceObject Strategies to eliminate hepatitis C virus infection in the Americas(2023) DIAZ, Luis Antonio; GARCIA, Sergio; KHAN, Rayan; AYARES, Gustavo; MONASTERIO, Javier Uribe; IDALSOAGA, Francisco; FUENTES, Eduardo; MEDEL, Maria Paz; RAMIREZ, Carolina; LAZO, Mariana; FERRECCIO, Catterina; MENDIZABAL, Manuel; DIRCHWOLF, Melisa; GUERRA, Patricia; OLIVEIRA, Claudia; PESSOA, Mario; ALVARES-DA-SILVA, Mario; SEBASTIANI, Giada; BRAHMANIA, Mayur; RAMJI, Alnoor; NIAZI, Mina; KO, Hin Hin; FELD, Jordan J.; RESTREPO, Juan Carlos; RAMIREZ, Wagner; ALFARO, Omar; CASTELLANOS-FERNANDEZ, Marlen; CARRERA, Enrique; AGUIRRE, Jose Roberto; CARDONA, Katherine Emilia Maldonado; SANCHEZ, Abel; SANCHEZ, Marco; ANDARA, Maria Teresa; CASTRO-NARRO, Graciela; CHAVEZ-TAPIA, Norberto Carlos; MENDEZ-SANCHEZ, Nahum; ADAMES, Enrique; LOMBARDO, Julissa; GIRALA, Marcos; MORAN, Elias; PADILLA, P. Martin; DIAZ-FERRER, Javier; TAGLE, Martin; MAINARDI, Victoria; HERNANDEZ, Nelia; MARTINEZ, Edmundo; ALVARADO-TAPIAS, Edilmar; ROBERT, Leon; HERNANDEZ-TEJERO, Maria; SICILIA, Mauricio Garcia Saenz De; ZHANG, Wei; BAJAJ, Jasmohan S.; TAPPER, Elliot; IZZY, Manhal; GISH, Robert G.; ATTAR, Bashar; COTTER, Thomas; KAMATH, Patrick S.; SINGAL, Ashwani; BATALLER, Ramon; MEZZANO, Gabriel; SOZA, Alejandro; LAZARUS, Jeffrey; ARRESE, Marco; ARAB, Juan Pablo- 52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B(2013) PIRATVISUTH, Teerha; KOMOLMIT, Piyawat; TANWANDEE, Tawesak; SUKEEPAISARNJAROEN, Wattana; CHAN, Henry L. Y.; PESSOA, Mario G.; FASSIO, Eduardo; ONO, Suzane K.; BESSONE, Fernando; DARUICH, Jorge; ZEUZEM, Stefan; CHEINQUER, Hugo; PATHAN, Rashidkhan; DONG, Yuhong; TRYLESINSKI, AldoBackground and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response. The efficacy and safety of this approach applied to telbivudine treatment has not been investigated. Methods: A multinational, phase IV, single-arm open-label study (ClinicalTrials.gov ID NCT00651209) was undertaken in HBeAg-positive, nucleoside-naive adult patients with chronic hepatitis B. Patients received telbivudine (600 mg once-daily) for 24 weeks, after which those with undetectable serum HBV DNA (<300 copies/mL) continued to receive telbivudine alone while those with detectable DNA received telbivudine plus tenofovir (300 mg once-daily). Outcomes were assessed at Week 52. Results: 105 patients commenced telbivudine monotherapy, of whom 100 were included in the efficacy analysis. Fifty-five (55%) had undetectable HBV DNA at Week 24 and continued telbivudine monotherapy; 45 (45%) received tenofovir intensification. At Week 52, the overall proportion of undetectable HBV DNA was 93% (93/100) by last-observation-carried-forward analysis (100% monotherapy group, 84% intensification group) and no virologic breakthroughs had occurred. ALT normalization occurred in 77% (87% monotherapy, 64% intensification), HBeAg clearance in 43% (65% monotherapy, 16% intensification), and HBeAg seroconversion in 39% (62% monotherapy, 11% intensification). Six patients had HBsAg clearance. Myalgia was more common in the monotherapy group (19% versus 7%). No decrease in the mean glomerular filtration rate occurred in either treatment group at Week 52. Conclusions: Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B.
- Prólogo: Una colaboración entre CLD y la Asociación Latinoamericana para el Estudio del Hígado (ALEH)(2019) PESSOA, M.G.; MENDIZáBAL, M.
- Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America(2023) MENDIZABAL, Manuel; THOMPSON, Marcos; GONZALEZ-BALLERGA, Esteban; ANDERS, Margarita; CASTRO-NARRO, Graciela E.; PESSOA, Mario G.; CHEINQUER, Hugo; MEZZANO, Gabriel; PALAZZO, Ana; RIDRUEJO, Ezequiel; DESCALZI, Valeria; VELASCO, Jose A. Velarde-Ruiz; MARCIANO, Sebastian; MUNOZ, Linda; I, Maria Schinoni; PONIACHIK, Jaime; PERAZZO, Rosalia; CERDA, Eira; FUSTER, Francisco; VARON, Adriana; GARCIA, Sandro Ruiz; SOZA, Alejandro; CABRERA, Cecilia; GOMEZ-ALDANA, Andres J.; BELTRAN, Flor de Maria; GERONA, Solange; COCOZZELLA, Daniel; BESSONE, Fernando; HERNANDEZ, Nelia; ALONSO, Cristina; FERREIRO, Melina; ANTINUCCI, Florencia; TORRE, Aldo; MOUTINHO, Bruna D.; BORGES, Silvia Coelho; GOMEZ, Fernando; MURGA, Maria Dolores; PINERO, Federico; SOTERA, Gisela F.; OCAMPO, Jhonier A.; MOLLINEDO, Valeria A. Cortes; SIMIAN, Daniela; SILVA, Marcelo O.To achieve WHO's goal of eliminating hepatitis C virus (HCV), innovative strategies must be designed to diagnose and treat more patients. Therefore, we aimed to describe an implementation strategy to identify patients with HCV who were lost to follow-up (LTFU) and offer them re-linkage to HCV care. We conducted an implementation study utilizing a strategy to contact patients with HCV who were not under regular follow-up in 13 countries from Latin America. Patients with HCV were identified by the international classification of diseases (ICD-9/10) or equivalent. Medical records were then reviewed to confirm the diagnosis of chronic HCV infection defined by anti-HCV+ and detectable HCV-RNA. Identified patients who were not under follow-up by a liver specialist were contacted by telephone or email, and offered a medical reevaluation. A total of 10,364 patients were classified to have HCV. After reviewing their medical charts, 1349 (13%) had undetectable HCV-RNA or were wrongly coded. Overall, 9015 (86.9%) individuals were identified with chronic HCV infection. A total of 5096 (56.5%) patients were under routine HCV care and 3919 (43.5%) had been LTFU. We were able to contact 1617 (41.3%) of the 3919 patients who were LTFU at the primary medical institution, of which 427 (26.4%) were cured at a different institutions or were dead. Of the remaining patients, 906 (76.1%) were candidates for retrieval. In our cohort, about one out of four patients with chronic HCV who were LTFU were candidates to receive treatment. This strategy has the potential to be effective, accessible and significantly impacts on the HCV care cascade.